Drugs / Moxifloxacin
Moxifloxacin
also known as
Avelox · BAY12-8039 · Moxifloxacin hydrochloride · Vigamox · MXF · Mfx · Izilox · AL-15469A · +25 more
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER | — | 2003-02-28 – 2016-09-27 | fda.gov ↗ |
| Approved | US (FDA) | AVELOX | — | 1999-12-10 | fda.gov ↗ |
Trials 265 · started per year
today
US approved 1999
1
2
3
8
8
12
11
15
14
11
11
14
13
19
6
12
7
14
6
13
6
12
10
13
16
7
1
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1137 trials · 13 met primary | ||||||
| Phase 1 | NCT07760246 | Aug → Dec 2026 expected | — | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT07422298 | Feb → Jun 2026 overdue | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT07305831 | Jan → Apr 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07229157 | Oct 2025 → Aug 2026 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT07063238 | Aug → Dec 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07023029 | Jun → Sep 2025 | sickle cell disease, thalassemia | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06846866 | Feb → Oct 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06746402 | Feb → Sep 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06589726 | Sep → Dec 2024 | — | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT06601192 | Jul 2024 → Feb 2025 | respiratory syncytial virus infectious disease | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Show all 137 trials opens the full record — a long page | ||||||
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06681688 | Jul 2024 → Jun 2025 overdue | cataract | Inder Paul Singh, M.D. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00396084 | Feb 2004 → Nov 2007 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 226 trials · 4 met primary · 3 missed | ||||||
| Phase 2 | NCT07485010 | Apr 2027 → Apr 2031 expected | pulmonary non-tuberculous mycobacterial infection | The University of Queensland | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07595042 | Jul 2026 → Jun 2029 expected | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07227779 | Jul 2026 → Mar 2028 expected | HIV infectious disease, meningeal tuberculosis | David Boulware | Recruiting | No outcome recorded |
| Phase 2 | NCT07129629 | Aug 2025 → Dec 2026 expected | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06917495 | Apr 2025 → Dec 2027 expected | tuberculosis, spinal | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07559149 | Jul 2024 → Feb 2025 | corneal ulcer | Gadjah Mada University | Completed | No outcome recorded |
| Phase 2 | NCT06114628 | Jan 2024 → Feb 2027 expected | pulmonary tuberculosis | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT05807399 | Apr 2023 → Oct 2027 expected | pulmonary tuberculosis | Michael Hoelscher | Recruiting | No outcome recorded |
| Phase 2 | NCT05382312 | Jul 2022 → May 2025 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT04204122 | Jun 2020 → Mar 2025 | graft versus host disease | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT03405168 | Jan → Jul 2018 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT02371681 | Feb 2015 → Sep 2017 | pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02193776 | Oct 2014 → Feb 2016 | tuberculosis | Global Alliance for TB Drug Development | Completed | Met primary |
| Phase 2 | NCT02595359 | Jan 2013 → Jun 2018 | endophthalmitis | Federal University of Pernambuco | Completed | No outcome recorded |
| Phase 2 | NCT01498419 | Mar 2012 → Apr 2013 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | Met primary |
| Phase 2 | NCT01238783 | Jan → Dec 2011 | bacterial conjunctivitis | Alcon Research | Withdrawn | No outcome recorded |
| Phase 2 | NCT01158755 | Oct 2010 → Dec 2011 | meningeal tuberculosis | Padjadjaran University | Completed | No outcome recorded |
| Phase 2 | NCT01215851 | Oct 2010 → May 2011 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | Met primary |
| Phase 2 | NCT01017731 | Nov 2009 → Apr 2010 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00728507 | Nov 2009 → Apr 2013 | tuberculosis | Johns Hopkins University | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT00458900 | Jul 2007 → Sep 2012 | pneumonia | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 2 | NCT00144417 | Feb 2006 → Jun 2007 | tuberculosis | Centers for Disease Control and Prevention | Completed | Missed primary |
| Phase 2 | NCT00306319 | Jan → May 2006 | tuberculosis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00082173 | Oct 2004 → Sep 2007 | tuberculosis | Johns Hopkins University | Completed | Met primary |
| Phase 2 | NCT00164463 | Jul 2004 → Aug 2007 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00140309 | Jul 2003 → Dec 2005 | pulmonary tuberculosis | Centers for Disease Control and Prevention | Completed | Missed primary |
| Phase 2/38 trials · 2 met primary | ||||||
| Phase 2/3 | NCT06441006 | Oct 2025 → Aug 2031 expected | multidrug-resistant tuberculosis, pulmonary tuberculosis | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05766267 | Nov 2023 → Dec 2026 expected | pulmonary tuberculosis | Centers for Disease Control and Prevention | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04207112 | Oct 2020 → Aug 2022 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, pulmonary tuberculosis | Medecins Sans Frontieres, Netherlands | Completed | No outcome recorded |
| Phase 2/3 | NCT04310930 | Mar 2020 → Jun 2029 expected | pulmonary non-tuberculous mycobacterial infection | The University of Queensland | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04879030 | Jan → Aug 2020 | chronic obstructive pulmonary disease | Haiphong University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2/3 | NCT04081077 | Aug 2019 → Sep 2022 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, pulmonary tuberculosis | Medecins Sans Frontieres, Netherlands | Unknown | No outcome recorded |
| Phase 2/3 | NCT03338621 | Jul 2018 → Jul 2021 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | Met primary |
| Phase 2/3 | NCT02589782 | Jan 2017 → Aug 2022 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, pulmonary tuberculosis | Medecins Sans Frontieres, Netherlands | Completed | Met primary |
| Phase 342 trials · 5 met primary · 2 missed | ||||||
| Phase 3 | NCT07274020 | Dec 2025 → Dec 2026 expected | bronchiectasis | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07268664 | Dec 2025 → May 2028 expected | pulmonary tuberculosis, rifampicin-resistant tuberculosis | Beijing Chest Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07209761 | Oct 2025 → May 2027 expected | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05821478 | May 2025 → Feb 2027 expected | hidradenitis suppurativa | Institut Pasteur | Recruiting | No outcome recorded |
| Phase 3 | NCT06253715 | Jan 2025 → Sep 2027 expected | lymph node tuberculosis, pulmonary tuberculosis | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT05917340 | Mar 2024 → Sep 2027 expected | meningeal tuberculosis | Indian Council of Medical Research | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05575518 | Aug 2023 → Dec 2025 | HIV infectious disease, tuberculosis | Stellah Mpagama | Unknown | No outcome recorded |
| Phase 3 | NCT02590523 | Jan 2023 → Jan 2024 | cataract, endophthalmitis | Panhandle Eye Group, LLP | Suspended | No outcome recorded |
| Phase 3 | NCT05081401 | May 2022 → Dec 2026 expected | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05114720 | Nov 2021 → Nov 2025 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT04856644 | Jan 2020 → Dec 2023 overdue | pulmonary tuberculosis | Kaohsiung Veterans General Hospital. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03491995 | Apr 2018 → Apr 2023 | Helicobacter pylori infectious disease | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT02754765 | Dec 2016 → Jun 2023 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Doctors Without Borders | Completed | Mixed |
| Phase 3 | NCT02563327 | May 2016 → Aug 2021 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT02410772 | Jan 2016 → Jul 2020 | tuberculosis | Centers for Disease Control and Prevention | Completed | Mixed |
| Phase 3 | NCT02342886 | Feb 2015 → Jan 2018 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 3 | NCT01573910 | May 2012 → Apr 2014 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01298336 | Mar 2011 → Mar 2019 | pulmonary non-tuberculous mycobacterial infection | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 3 | NCT01069900 | Jul 2010 → Jan 2015 | infectious peritonitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01154959 | Feb 2010 → Dec 2015 | pulmonary tuberculosis | Tuberculosis Research Centre, India | Completed | No outcome recorded |
| Phase 3 | NCT00876850 | Jul 2009 → Jul 2010 | — | Paratek Pharmaceuticals Inc | Withdrawn | No outcome recorded |
| Phase 3 | NCT00828971 | Nov 2008 → Sep 2009 | infectious disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00759148 | Oct 2008 → Mar 2010 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00717561 | Feb 2008 → May 2009 | pneumonia | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00864383 | Jan 2008 → Oct 2013 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | Missed primary |
| Phase 3 | NCT00455806 | Jan 2007 → Feb 2008 | Helicobacter pylori infectious disease, chronic gastritis | Technical University Dresden | Unknown | No outcome recorded |
| Phase 3 | NCT00453349 | Jan 2007 → May 2008 | pelvic inflammatory disease | Bayer | Completed | Met primary |
| Phase 3 | NCT00398411 | Oct 2006 → Dec 2008 | Hodgkins lymphoma, bacterial infectious disease, non-Hodgkin lymphoma, plasma cell myeloma | University of Cologne | Completed | Met primary |
| Phase 3 | NCT00402727 | Sep 2006 → Jun 2008 | abscess, skin infection, ulcer disease | Bayer | Completed | Met primary |
| Phase 3 | NCT00492726 | Jul 2006 → Feb 2009 | infectious disease | Bayer | Completed | Met primary |
| Phase 3 | NCT00335088 | Jun 2006 → May 2007 | eye infectious disorder | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| Phase 3 | NCT00332293 | May → Dec 2006 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00629135 | Nov 2005 → Aug 2011 | abscess | Hannover Medical School | Completed | No outcome recorded |
| Phase 3 | NCT00331916 | Nov 2005 → May 2007 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00769171 | Oct 2005 → Dec 2006 | infectious peritonitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00492024 | Jan 2005 → Mar 2008 | sinusitis | Bayer | Completed | Missed primary |
| Phase 3 | NCT00473460 | Oct 2004 → Jan 2007 | chronic bronchitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00323219 | Jan 2004 → Dec 2012 | cellulitis | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT00431678 | Jan 2004 → Jul 2005 | pneumonia | Bayer | Completed | Met primary |
| Phase 3 | NCT00683865 | Apr 2003 → Oct 2004 | pelvic inflammatory disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01045902 | Feb 2001 → Jan 2005 | aspiration pneumonia, lung abscess | Bayer | Completed | No outcome recorded |
| Phase 435 trials · 2 met primary · 1 missed | ||||||
| Phase 4 | NCT06153069 | Nov 2025 → Nov 2027 expected | tuberculosis | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05381194 | Dec 2022 → Dec 2027 expected | multidrug-resistant tuberculosis | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05398679 | Aug 2022 → Dec 2026 expected | infective endocarditis | Fundacion Clinic per a la Recerca Biomédica | Recruiting | No outcome recorded |
| Phase 4 | NCT05184491 | Oct 2021 → Feb 2022 | Helicobacter pylori infectious disease | National Liver Institute, Egypt | Unknown | No outcome recorded |
| Phase 4 | NCT03830671 | Mar 2019 → Jun 2022 | multidrug-resistant tuberculosis | Beijing Chest Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03640650 | Aug 2018 → Mar 2021 | cataract | PeriPharm | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04403334 | Jan → Apr 2018 | endophthalmitis, poisoning, senile cataract | Peregrine Eye and Laser Institute | Completed | No outcome recorded |
| Phase 4 | NCT03363295 | Jul 2017 → Dec 2019 | cataract, endophthalmitis, macular retinal edema | Federal University of Pernambuco | Completed | No outcome recorded |
| Phase 4 | NCT03237182 | Jun 2017 → Dec 2022 | multidrug-resistant tuberculosis | Centre for the AIDS Programme of Research in South Africa | Terminated | No outcome recorded |
| Phase 4 | NCT02839421 | Dec 2015 → May 2019 | periodontitis, aggressive | Facultad Nacional de Salud Publica | Unknown | No outcome recorded |
| Phase 4 | NCT01936480 | Oct 2013 → Jun 2019 | cardiac rhythm disease | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02331823 | Jun 2013 → Dec 2015 | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 4 | NCT01854710 | May → Jul 2013 | — | Alexza Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 4 | NCT01860703 | Nov → Dec 2012 | — | ApoPharma | Completed | No outcome recorded |
| Phase 4 | NCT01859702 | Apr → Aug 2012 | cataract | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT02016157 | Sep 2011 → Nov 2012 | chronic periodontitis | Sri Hasanamba Dental College and Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02223702 | May 2011 → May 2012 | periodontitis, aggressive | Kocaeli University | Completed | Met primary |
| Phase 4 | NCT01329250 | May 2011 → Jun 2015 | tuberculosis | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 4 | NCT01130922 | Mar → Jun 2010 | — | University Ghent | Completed | No outcome recorded |
| Phase 4 | NCT00895089 | May 2009 → Dec 2010 | liver abscess (disease) | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| Phase 4 | NCT00805558 | Feb → Dec 2009 | chronic periodontitis | Facultad Nacional de Salud Publica | Completed | No outcome recorded |
| Phase 4 | NCT00952796 | Jan 2009 → Dec 2010 | peritonitis | Kaohsiung Medical University Chung-Ho Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00840580 | Jan → Sep 2009 | cataract | Alcon Research | Completed | Missed primary |
| Phase 4 | NCT00798577 | Oct 2008 → Feb 2009 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00752947 | Sep 2008 → Mar 2010 | pneumonia | Beijing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00870103 | Sep 2008 → Feb 2009 | cataract | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01302951 | Jul 2008 → Jul 2010 | flucloxacilline toxicity | University Hospital, Saarland | Completed | No outcome recorded |
| Phase 4 | NCT00656747 | Mar 2008 → Dec 2010 | chronic bronchitis | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00564447 | Dec 2007 | bacterial infectious disease, eye infectious disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00347828 | Jun 2006 | eye infectious disorder | Ophthalmic Consultants of Boston | Unknown | No outcome recorded |
| Phase 4 | NCT00312338 | Jun 2006 → Jun 2007 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00493038 | Feb 2006 → Jan 2008 | bacterial infectious disease, sinusitis | Bayer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00280514 | Jan 2006 → Dec 2009 | abscess | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00668304 | Jun 2004 → Jan 2005 | maxillary sinusitis | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00665327 | Nov 2002 → Apr 2004 | pneumonia | Bayer | Completed | No outcome recorded |
| Phase not applicable15 trials · 1 met primary | ||||||
| — | NCT07608172 | May 2026 → Jun 2028 expected | pulmonary tuberculosis | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| — | NCT07585461 | Apr 2026 → Dec 2028 expected | AIDS-related disorder, Mycobacterium avium complex disease | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| — | NCT07394257 | Oct 2025 → Apr 2026 overdue | corneal ulcer | Minia University | Recruiting | No outcome recorded |
| — | NCT07126639 | Sep 2025 → Sep 2027 expected | — | Wuhan Pulmonary Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07014735 | Apr 2023 → May 2026 | hyperglycemia, torsades de pointes, type 2 diabetes mellitus | Richmond Pharmacology Limited | Terminated | No outcome recorded |
| — | NCT05428683 | Dec 2020 → Aug 2021 | — | Emad Abdel Aal Saliem | Completed | No outcome recorded |
| — | NCT04187469 | Mar 2020 → Feb 2023 | pulmonary tuberculosis | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT02359331 | Aug 2014 → Dec 2022 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Terminated | No outcome recorded |
| — | NCT02373280 | Aug 2014 → Apr 2027 expected | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| — | NCT01653990 | Jul → Sep 2012 | long QT syndrome | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT01259141 | Oct 2010 → Dec 2014 | Mycoplasma pneumoniae pneumonia | Capital Medical University | Completed | No outcome recorded |
| — | NCT02349685 | Jan 2010 → Jun 2014 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT00466570 | Apr 2007 → ? | — | Stanford University | Withdrawn | No outcome recorded |
| — | NCT00062231 | Apr 2002 → Oct 2006 | cancer of unknown primary site, infectious disease, leukemia, myelodysplastic syndrome +5 | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | Met primary Stop: Enrollment |
| — | NCT00414011 | ? → Feb 2005 | corneal disorder | Walter Reed Army Medical Center | Completed | No outcome recorded |
| Comparator or background therapy302 trials | ||||||
| Phase 0 | NCT04966325 Comparator | Sep → Dec 2021 | gout | LG Chem | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT07708272 Comparator | Jul → Dec 2026 expected | myelofibrosis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07513207 Comparator | Apr → Jul 2026 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT07594847 Comparator | Mar → Sep 2026 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Show all 302 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2024-07-18 | Paratek Pharmaceuticals Inc | Results Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia paratekpharma.com ↗ |
| 2019-11-13 | Global Alliance for TB Drug Development | Results Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine tballiance.org ↗
Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine. |
| 2019-02-06 | Paratek Pharmaceuticals Inc | Results New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek's NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections paratekpharma.com ↗
OPTIC demonstrated that NUZYRA was non-inferior to moxifloxacin for the treatment of adults with CABP and was safe and well-tolerated. |
| 2018-05-22 | Paratek Pharmaceuticals Inc | Results Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity paratekpharma.com ↗
The data showed similar, high rates of response for the early clinical response (ECR) and post therapy evaluation (PTE, also known as test-of-cure) endpoints in both the omadacycline and moxifloxacin treatment groups, regardless of the severity of disease. |
| 2016-12-16 | Global Alliance for TB Drug Development | Results Clinical Trial of BPaMZ Regimen Will Replace Phase 3 STAND Trial tballiance.org ↗
In light of these results, where the BPaMZ regimen appears to be much more promising compared to the PaMZ (pretomanid + moxifloxacin + pyrazinamide) regimen, the STAND trial testing the PaMZ regimen will not be reopened to new patients. |
| 2016-10-25 | Harrow Inc | Results Imprimis' Dropless Therapy Shows Significant Advantages in a Large Peer-Reviewed Study harrow.com ↗
The study evaluated 1,541 eyes from 922 patients and demonstrated that in nearly 92% of cases (n=1413/1541), supplemental medication was not required after surgery. |
| 2016-07-22 | Harrow Inc | Results Peer-Reviewed Study of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared to Drops harrow.com ↗
In the following month, Tri-Moxi-Vanc and drops produced no statistically significant difference in intraocular pressure immediately ( P =0.81) or over time ( P =0.74), central macular thickness at 1 week and 1 month ( P =0.18), central corneal thickness ( P =0.92), or reported pain ( P =0.67). |
| 2016-05-12 | Harrow Inc | Results Clinical Study of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction in Cystoid Macular Edema in Patients Following Cataract Surgery harrow.com ↗
The CME rate was 0.5% in the group (n=600) receiving Dropless Therapy (intravitreal Tri-Moxi-Vanc) with post-operative NSAID drops only, thereby achieving statistical significance (P=0.003) in CME prevention versus traditional steroid and NSAID drops. |
| 2015-03-18 | Global Alliance for TB Drug Development | Results The Lancet: Results of Phase 2b Trial of Novel TB Regimen PaMZ Show Potential to Shorten, Improve TB Treatment tballiance.org ↗
Nearly twice (71 percent) as many TB patients treated with PaMZ had no TB in their sputum when cultured at the end of the 2-month course of the trial compared to patients treated with standard therapy (38 percent). |
| 2015-02-03 | Harrow Inc | Results Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops™ Combination Eye Drop Formulations Following LASIK Surgery harrow.com ↗
Dr. Wiley concluded that Imprimis' Tri-Moxi and Pred-Moxi combination eye drop formulations produced equivalent outcomes compared to standard follow-up care measurements observed in traditional post-LASIK eye drop treatments. |
| 2014-10-24 | Harrow Inc | Results Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting harrow.com ↗
SAN DIEGO , Oct. 24, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today reported on clinical findings demonstrating the safety and benefits of Dropless cataract surgery and provided an update resulting from the recent American Academy of Ophthalmology (AAO) annual meeting held in Chicago , Illinois. |
| 2014-09-07 | Global Alliance for TB Drug Development | Results Results of Phase 3 Clinical Trial of New Tuberculosis Drug Regimen Published in New England Journal of Medicine tballiance.org ↗
Substituting moxifloxacin alone in the standard TB drug regimen did not shorten treatment time from six to four months |
| 2012-07-23 | Global Alliance for TB Drug Development | Results Trial Signals Major Milestone in Hunt for New TB Drugs tballiance.org ↗
These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients. |
All press releases naming this drug 21 releases
Evidence & citations 37 cited values
Every value below carries the sentence it was read from. 578 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moxifloxacin | “Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane Ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon...” NCT05331859 ↗549“This two-stage study will compare consented research participants with tuberculous meningitis receiving experimental Bedaquiline (B), Pretomanid (Pa), Linezolid (L);...” NCT07227779 ↗ “This randomized, three treatment, three period, six sequence crossover study with placebo, a positive control (moxifloxacin 400 mg) and tafamidis (400 mg, to achieve a...” PMID 25546001 ↗ Jun 2015 “This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv)...” NCT02168816 ↗ “The objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid,...” NCT05381194 ↗ “Fourteen-day esomeprazole, tripotassium dicitrate bismuthate, metronidazole and tetracycline (EBMT) therapy or esomeprazole, moxifloxacin and amoxicillin (MEA) therapy was...” PMID 26452405 ↗ Oct 2015 “This study aims to evaluate whether adding a fluoroquinolone (levofloxacin or moxifloxacin) to the standard triple therapy improves early clinical outcomes in HIV-infected...” NCT07585461 ↗ “Experimental arms are seven oral regimens with a five-drug combination of the following: bedaquiline, linezolid, a fluoroquinolone (moxifloxacin or levofloxacin), cycloserine,...” NCT05081401 ↗ “Bedaquiline 400 mg once daily for 2 weeks then 200 mg thrice a week for 24 weeks + Pretomanid 200 mg QD for 26 weeks + Linezolid 600 mg once daily for 26 weeks + Moxifloxacin...” NCT07209761 ↗ “The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.).” NCT01761214 ↗ “using regimens containing isoniazid (INH \[H\]), rifampin (RIF \[R\]), pyrazinamide (PZA \[Z\]), moxifloxacin (MXF \[M\]), and ethambutol (EMB \[E\]).” NCT02371681 ↗ |
| Known as | AL-15469A | “AL-15469A for the Treatment of Bacterial Conjunctivitis” NCT00331916 ↗ |
| Known as | Avalox | “Drug: Moxifloxacin (Avalox®)” NCT01965431 ↗1“Moxifloxacin (Avalox®)” NCT02172144 ↗ |
| Known as | Avalox (moxifloxacin) | “Avalox® (moxifloxacin)” NCT00534287 ↗ |
| Known as | Avelox | “Moxifloxacin (Avelox, Bayer): will be administered to patients per os as tablet as single or multiple doses of 400 mg.” NCT00280514 ↗30“Moxifloxacin (Avelox) is a drug with a known potential to create a mild QTc interval prolongation” NCT01756495 ↗ “Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks” NCT00473460 ↗ “Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days” NCT00453349 ↗ “1\) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days.” NCT02136875 ↗ “Avelox (moxifloxacin), an anti-biotic approved for use by the FDA” NCT00158093 ↗ “Using Open-label Moxifloxacin (Avelox®) as a Positive Control” NCT01290900 ↗ “Moxifloxacin (Avelox®) is administered as positive control.” NCT01516255 ↗ “either Avelox (moxifloxacin hydrochloride) or placebo” NCT01928914 ↗ “Using Moxifloxacin (Avelox®) as a Positive Control” NCT01265641 ↗ “Moxifloxacin, avelox® 400 mg qd 7 days (D1-D7)” NCT02373280 ↗ |
| Known as | Avelox i.v. | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | Avelox(TM) | “oral moxifloxacin 400mg film coated tablets - Avelox(TM)” NCT03709927 ↗ |
| Known as | BAY12-8039 | “Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks” NCT00473460 ↗19“Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days” NCT00453349 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00717561 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT00402727 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00656747 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00828971 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00431678 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00665327 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00769171 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00668304 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT01073891 ↗ |
| Known as | Fortymox | “Moxifloxacin 0.5% eye drops (Fortymox; Orchidia, Egypt)” NCT07812129 ↗ |
| Known as | Izilox | “then one 400 mg moxifloxacin tablet (Izilox®, Bayer Pharmaceuticals Corporation) administered orally on Day 14” NCT02091310 ↗2“1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning.” NCT01103830 ↗ “moxifloxacin (Izilox daily dose 400mg)” NCT05821478 ↗ |
| Known as | MFLX | “In vitro studies have suggested the corneal cytotoxicity of third-generation fluoroquinolone levofloxacin (LVFX) and fourth-generation fluoroquinolone moxifloxacin...” PMID 21060669 ↗ Oct 2010 |
| Known as | Mfx | “The abbreviation of the name of the 3 drugs in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）” NCT03830671 ↗3“A six - month regimen containing bedaquiline (BDQ), pretomanid (Pa), linezolid (LZD), and moxifloxacin (MFX)” NCT07126639 ↗ “Regimen A (bedaquiline [Bdq]+linezolid [Lzd]+moxifloxacin [Mfx]+cycloserine [Cs]+pyrazinamide [Pza])” PMID 37567554 ↗ Aug 2023 “Moxifloxacin (MFX):” NCT07268664 ↗ |
| Known as | Minims | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | MOX | “The interventions are Scaling and Root Planing (SRP) combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days.” NCT02839421 ↗ |
| Known as | Moxeza | “An alternative formulation of 0.5% moxifloxacin ophthalmic solution (Moxeza, MOXI-AF, Alcon Laboratories, Inc., Fort Worth, TX, USA) containing xanthan gum to prolong retention...” PMID 21681652 ↗ Jun 2011 |
| Known as | MOXI-AF | “An alternative formulation of 0.5% moxifloxacin ophthalmic solution (Moxeza, MOXI-AF, Alcon Laboratories, Inc., Fort Worth, TX, USA) containing xanthan gum to prolong retention...” PMID 21681652 ↗ Jun 2011 |
| Known as | Moxifloxacin (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | moxifloxacin (Avelox) | “moxifloxacin (Avelox)” NCT01761214 ↗1“Moxifloxacin (Avelox)” NCT02168816 ↗ |
| Known as | Moxifloxacin 400 mg (Avelox, Tablet) | “Moxifloxacin 400 mg (Avelox, Tablet)” NCT01871701 ↗ |
| Known as | Moxifloxacin AF | “Moxifloxacin AF Ophthalmic Solution compared to Moxifloxacin AF Vehicle” NCT00759148 ↗ |
| Known as | Moxifloxacin hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | Moxifloxacin hydrochloride | “Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.” NCT04214821 ↗18“Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.” NCT04212429 ↗ “One 400 mg moxifloxacin tablet (AVELOX®, moxifloxacin hydrochloride, Bayer Pharmaceuticals Corporation) will be administered orally on the morning of Day 1” NCT01986894 ↗ “A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.” NCT03613649 ↗ “one such compound includes triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin (TriMoxiVanc).” NCT02819908 ↗ “Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose” NCT02910635 ↗ “either Avelox (moxifloxacin hydrochloride) or placebo” NCT01928914 ↗ “0.5% moxifloxacin hydrochloride ophthalmic solution” NCT00630019 ↗ “receive oral moxifloxacin hydrochloride once daily” NCT00324324 ↗ “Avelox (moxifloxacin hydrochloride) tablet” NCT01148537 ↗ “VIGAMOX {0.5% moxifloxacin hydrochloride}” NCT06681688 ↗ |
| Known as | Moxifloxacin hydrochloride (Vigamox) | “Moxifloxacin hydrochloride (Vigamox)” NCT00758199 ↗ |
| Known as | MOXIFLOXACIN HYDROCHLORIDE HYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | moxifloxacin tablets | “moxifloxacin tablets” NCT02331823 ↗ |
| Known as | Moxifloxacine | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | Moxifloxacino | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | Moxivig | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | MXF | “The aim of the study is to provide data on the pharmacokinetics (PK) of moxifloxacin (MXF) in serum and liver tissue of patients undergoing liver resection due to primary or...” NCT01302951 ↗6“We evaluated the efficacies of oral prophylactic treatment with amoxicillin (AMX), clindamycin (CLI), and moxifloxacin (MXF) in the prevention of bacteremia following dental...” PMID 16940094 ↗ Sep 2006 “BACKGROUND: This study was designed to evaluate primarily the safety and also the efficacy of moxifloxacin (MXF) in children with complicated intra-abdominal infections (cIAIs).” PMID 29356761 ↗ Aug 2018 “Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB).” PMID 23927582 ↗ Oct 2013 “Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic.” NCT00816426 ↗ “intravenous/oral moxifloxacin (MXF, N = 110) 400 mg q.d.” PMID 23180507 ↗ Nov 2012 “moxifloxacin (MXF \[M\])” NCT02371681 ↗ |
| Known as | NSC-758875 | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | Vigamox | “Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane Ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon...” NCT05331859 ↗13“Phacoemulsification surgery patients in the experimental group (Group A) received a 0.03 mL intracameral injection of undiluted moxifloxacin from a sealed bottle immediately...” PMID 32818353 ↗ Jan 2021 “The aim of this study is to evaluate the efficacy and safety of the use of topical moxifloxacin 0.5% ophthalmic solution (Vigamox®) in the prophylaxis of acute endophthalmitis...” NCT05162625 ↗ “About 20 patients treated by Moxifloxacin ophthalmic solution 0.5% (Vigamox) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.” NCT00892918 ↗ “The study evaluates the use of intracameral Moxifloxacin 0.5% (Vigamox®) as prophylaxis in cases of endophthalmitis after open ocular trauma;” NCT05079854 ↗ “Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)” NCT02625467 ↗ “Vigamox (moxifloxacin hydrochloride ophthalmic solution)” NCT00575367 ↗ |
| Known as | Vigamox Ophthalmic Solution | “Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)” NCT00798577 ↗ |
| Known as | Vigamox(moxifloxacin hydrochloride ophthalmic solution) | “Vigamox(moxifloxacin hydrochloride ophthalmic solution)” NCT00575380 ↗ |
| Known as | Zimoxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Action | Inhibit | “It inhibits bacterial topoisomerase II (DNA gyrase)” NCT00816426 ↗ |
| Modality | Small molecule | “4th generation fluoroquinolones” NCT00414011 ↗ |
| Route | Oral | “This double-blind, multicenter trial compared the efficacy and safety of a single daily oral dose of moxifloxacin with oral combination therapy” PMID 23358983 ↗ Jan 2013 |